CELLECT BIOTECH/S ADR (NASDAQ:APOP) closed Tuesday’s trading session at $1.08 and had it announced last week that it has teamed up with the Washington University for upcoming clinical trials.
The company and Washington University have collaborated to prepare for the first ApoGraft- based bone marrow transplantation in the U.S. This means that the clinical trials will use Cellect’s ApoGraft stem cell selection technology which has never been used in a clinical trial in the U.S. The clinical trial aims to determine ApoGraft’s safety and tolerability in bone marrow transplantations.
Dr. John DiPersio, Washington University’s director of the Gene and Cellular Immunotherapy center, will lead the collaborative effort between Cellect and the university. The ApoGraft stem cell technology is aimed at preventing acute graft-versus-host disease after a bone marrow transplantation. Cellect previously announced positive interim safety and tolerability results from ongoing clinical trials outside the U.S. It also anticipates more positive interim data within the first half of 2019.
The clinical trial to evaluate safety and tolerability
The company plans to feature 12 patients in the open-label clinical trial, but the company plans to finalize the recruitment process within the second half of this year. The study will evaluate ApoGraft’s safety and tolerability in patients suffering from hematological malignancies, especially those that require allogeneic hematopoietic stem cell transplantation.
“This is a very significant development for Cellect and demonstrates that our leading technology is garnering attention from the most influential clinical institutions in the U.S.,” stated Dr. Shai Yarkoni, Cellect’s CEO.
The study’s primary endpoint will be its incidence, severity, and frequency of adverse events related to the technology. Dr. Yarkoni also reported that the company had already observed positive results in its tests outside the U.S. The preliminary data revealed in October last year revealed that there were complete engraftment and no adverse events related to the procedure.
Cellect believes that the ApoGraft stem cell selection technology will change the lives of millions of patients. The company also believes that the technology will significantly improve bone marrow transplantation in the U.S. Bone marrow transplantation is the largest cell therapy segment in the U.S.